Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: Axcella Health (AXLA), Alnylam Pharma (ALNY) and Cytokinetics (CYTK)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Axcella Health (AXLAResearch Report), Alnylam Pharma (ALNYResearch Report) and Cytokinetics (CYTKResearch Report).

Axcella Health (AXLA)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Axcella Health today and set a price target of $10.00. The company’s shares closed last Friday at $1.71, close to its 52-week low of $1.35.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 4.4% and a 36.0% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Aurinia Pharmaceuticals, and Paratek Pharmaceuticals.

Axcella Health has an analyst consensus of Strong Buy, with a price target consensus of $8.50, a 391.3% upside from current levels. In a report issued on September 30, Wedbush also reiterated a Buy rating on the stock with a $9.00 price target.

See the top stocks recommended by analysts >>

Alnylam Pharma (ALNY)

Berenberg Bank analyst Zhiqiang Shu maintained a Hold rating on Alnylam Pharma today and set a price target of $184.00. The company’s shares closed last Friday at $200.16.

According to TipRanks.com, Shu ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -27.5% and a 18.4% success rate. Shu covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Monte Rosa Therapeutics, and Sensei Biotherapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alnylam Pharma with a $235.95 average price target.

Cytokinetics (CYTK)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Cytokinetics, with a price target of $75.00. The company’s shares closed last Friday at $48.45.

According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of -27.0% and a 20.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Bioline RX Ltd Sponsored ADR, and Lineage Cell Therapeutics.

Currently, the analyst consensus on Cytokinetics is a Strong Buy with an average price target of $68.11, representing a 40.0% upside. In a report issued on September 23, Mizuho Securities also maintained a Buy rating on the stock with a $80.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AXLA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed